SLC5A2 and chronic kidney disease: Until now, research into finding therapies that be used to treat all forms CKD has focused on improving cardiovascular outcomes and in slowing disease progression, mainly with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which also help to lower blood pressure, a driver of CKD progression, and more recent use of SGLT2 inhibitors.